Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer | Latest News RSS feed

Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer - Latest News


First line immunotherapy combination fails to improve overall survival in lung cancer

First line immunotherapy with durvalumab or the combination ... therapy for metastatic non-small cell lung cancer (NSCLC) while the use of two immunotherapy drugs without chemotherapy has been ... read more

Immunotherapy Combo Flops in Metastatic NSCLC

An immunotherapy combination failed to improve survival versus chemotherapy as initial treatment for patients with metastatic non-small cell lung cancer (NSCLC), results ... have come up with chemothe... read more

FDA approves Tecentriq-based combination for first-line treatment of lung cancer

The FDA approved atezolizumab in combination with bevacizumab ... regimen has demonstrated a significant survival benefit in the initial treatment of metastatic nonsquamous non-small cell lung cancer, ... read more

Looking for another news?


FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

“This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer,” said ... Phase III IMpower150 study, which show... read more


Genentech: FDA Approves Tecentriq in Combination for Some Lung Cancer Patients

Approval is based on results of the Phase III IMpower150 study, which showed that Tecentriq in combination ... a significant survival benefit in the initial treatment of metastatic non-squamous non-sm... read more

PKCδ enzyme linked to therapy resistance in lung cancer

They believe two existing therapies may hold promise for clinical studies for this deadly and common lung cancer for which relapse often occurs within one year following treatment. The study ... survi... read more

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

"It's been more than 20 years since there has been a new initial treatment option for extensive-stage small cell lung cancer ... study, which met its co-primary endpoints of overall survival ... read more

WVU Cancer Institute studies new treatment for colorectal cancer using novel drug combination

In a recent study, he and an international team of scientists investigated a new drug combination for treating metastatic colorectal cancer in patients who had no—or only temporary—success with conven... read more

Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

and progression-free survival (PFS) compared with chemotherapy alone in patients with previously untreated metastatic squamous non–small-cell lung cancer (NSCLC). The study, published in The New Engla... read more

Metastatic Prostate Cancer Target Identified for Combo Therapy

Studies in genetically engineered mouse models (GEMM) and data from human prostate cancer patients indicate that administering drugs targeting ... are due to metastases that are often resistant to tre... read more

AstraZeneca looks to salvage data from negative Imfinzi lung cancer study

British drugmaker AstraZeneca is doing a deep dive into data from an immunotherapy study in lung cancer ... difference in survival versus the chemotherapy arm than the two-drug combination did. read more

Cancer Research Highlight: AstraZeneca's Checkpoint Combo Fails To Help In Head And Neck

Recall that we got final confirmation that the phase 3 MYSTIC study was a failure, as durvalumab and tremelimumab did not improve survival in patients with metastatic non-small cell lung cancer. read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us